INOVIQ Sets Staged Path To Advance Ovarian Cancer Test Toward US Readiness
IIQ: $0.135 -1.82% · MC: $18M
INOVIQ says an independent US review found sample collection and handling differences were the main source of variability in its OC2200 study, and it has begun a staged program to optimise and verify its EXO-OC ovarian cancer test, targeting US laboratory test readiness by the first half of 2028. The company reported A$8 million in cash at quarter-end and said it received a further approximately A$2 million in R&D tax incentives after quarter-end; it is prioritising the test and its CAR-exosome program. Chairman Peter Gunzburg has taken on the interim Executive Chair role following Dr Leearne Hinch’s departure.

Comments